Mental Health Clinics in Bermuda Dunes, CA Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Agape Counseling Inc. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 79061 Avenue 42 Apt C, Bermuda Dunes, CA 92203 Phone: 951-496-6314 |
News Archive
Study examines impact of tobacco smoke carcinogen on mice
Although tobacco use is widely understood to be one of the leading causes of oral cancer, research on the prevention of tobacco-related oral cancer in experimental animals has traditionally been limited to examining the impact of synthetic carcinogens manufactured especially for cancer research, rather than on observing the effects of carcinogens that occur in tobacco smoke.
Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.
Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds
Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.
CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.
Shrink reveals image of StemDisc450 biomedical research tool
Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.
› Verified 4 days ago